{
    "nct_id": "NCT05337280",
    "official_title": "Feasibility of Assessing Breast Cancer Neoadjuvant Therapy Response Using Imagio Opto-Acoustic Imaging",
    "inclusion_criteria": "1. 18 years and older male or female patients;\n2. Ipsilateral intact biopsy-proven invasive breast cancer clinical T1-T4 (by standard of care imaging), including primary or recurrent disease.\n3. Patient eligible to receive neoadjuvant chemotherapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Known Stage IV disease (breast or other cancer);\n2. Have a condition or impediment (i.e., insect bites, poison ivy, open sores, chafing of the skin, scar, tattoos, moles, etc.); that could interfere with the intended field of view (within one probe length or 4 cm of the nodule);\n3. Patient has received chemotherapy for any type of cancer within 90 days from date of baseline Imagio OA/US exam;\n4. Is experiencing photo-toxicity associated with currently taking, or having taken, photosensitizing agents within the previous 72 hours such as sulfa, ampicillin, tetracycline;\n5. Is currently undergoing phototherapy;\n6. Has a history of any photosensitive disease (e.g., porphyria, lupus erythematosus);\n7. Is undergoing treatment for a photosensitive disease and is experiencing photosensitivity;\n8. Pregnancy;\n9. Patient has participated in a clinical study of an investigational drug or device within 3 months prior to screening visit that may have an impact on clinical outcomes.",
    "miscellaneous_criteria": ""
}